Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
August 4, 2025 2:10 PM EDTTD Cowen analyst Ritu Baral reiterated a Buy rating and $61.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).
The analyst comments "Our Take: We are highly encouraged by today's data which we believe bodes well for PBO-controlled POWER1 Ph2/3 vormatrigene data due by... More
Praxis Precision Medicines Inc. (PRAX) PT Raised to $33 at Wedbush
August 4, 2025 1:24 PM EDTWedbush analyst Laura Chico raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $33.00 (from $28.00) while maintaining a Underperform rating.
The analyst comments "Remain Underperform rated on PRAX, new $33 target. While the headline figure for seizure reduction with vormatrigine represented... More
Praxis Precision Medicines (PRAX) Misses Q2 EPS by 6c
August 4, 2025 9:05 AM EDTPraxis Precision Medicines (NASDAQ: PRAX) reported Q2 EPS of ($3.31), $0.06 worse than the analyst estimate of ($3.25).
For earnings history and earnings-related data on Praxis Precision Medicines (PRAX) click here.
... MorePraxis reports positive seizure reduction results from vormatrigine trial
August 4, 2025 8:10 AM EDTPraxis Precision Medicines Inc. (NASDAQ: PRAX) announced results from its Phase 2 RADIANT study of vormatrigine in patients with focal onset seizures. The 8-week study showed a 56.3% median reduction in seizure frequency, according to the company's statement.
Approximately 22% of patients achieved complete seizure elimination during the final 28 days of treatment. More than 54% of patients... More
